N-(4-(4-(2-(4-(trifluoromethyl)phenyl)acetyl)-1,4-diazepane-1-carbonyl)phenyl)quinoline-8-sulfonamide | 1260077-93-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-(4-(4-(2-(4-(trifluoromethyl)phenyl)acetyl)-1,4-diazepane-1-carbonyl)phenyl)quinoline-8-sulfonamide
• 英文别名: N-[4-[4-[2-[4-(trifluoromethyl)phenyl]acetyl]-1,4-diazepane-1-carbonyl]phenyl]quinoline-8-sulfonamide
• CAS: 1260077-93-7
• 化学式: C₃₀H₂₇F₃N₄O₄S
• 分子量: 596.63
• InChiKey: ODASHYHBZIKBEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  42
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  108
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• THERAPEUTIC COMPOUNDS AND COMPOSITIONS
  申请人：Salituro Francesco G.

  公开号：US20100331307A1

  公开（公告）日：2010-12-30

  Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.

  本文描述了调节丙酮酸激酶M2（PKM2）的化合物和含有这些化合物的组合物。本文还描述了利用调节PKM2的化合物治疗癌症的方法。
• PROCESS FOR PRODUCTION OF CARBONYL COMPOUND
  申请人：Sumitomo Chemical Company, Limited

  公开号：EP2266942A1

  公开（公告）日：2010-12-29

  A process for producing a carbonyl compound corresponding to an olefin, the process comprising reacting the olefin with molecular oxygen in a water-containing liquid phase comprising a palladium catalyst, a vanadium compound, and a heteropoly acid having a heteropoly anion represented by the Formula: [XaMbM'cOd]n- wherein X is any of elements selected from P, Si, and S; a represents an integer of 1 or 2; M and M' represent any of elements selected from Mo, W, V, Ta, and Nb; b and c represent an integer of 0 or more; d represents an integer of 1 or more; and n represents an integer of 1 or more.

  一种生产对应于烯烃的羰基化合物的工艺，该工艺包括在含水液相中使烯烃与分子氧反应，该含水液相由钯催化剂、钒化合物和杂多酸组成，杂多酸具有由式[XaMbM'cOd]n-代表的杂多阴离子：[XaMbM'cOd]n- 其中 X 是选自 P、Si 和 S 的元素；a 代表 1 或 2 的整数；M 和 M'代表选自 Mo、W、V、Ta 和 Nb 的元素；b 和 c 代表 0 或 0 以上的整数；d 代表 1 或 1 以上的整数；n 代表 1 或 1 以上的整数。
• QUINOLINE-8-SULFONAMIDE DERIVATES HAVING AN ANTICANCER ACTIVITY
  申请人：Agios Pharmaceuticals, Inc.

  公开号：EP3241554A1

  公开（公告）日：2017-11-08

  Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.

  本文描述了包含调节丙酮酸激酶 M2（PKM2）的化合物和组合物。本文还描述了使用调节 PKM2 的化合物治疗癌症的方法。
• 2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-SULFONAMIDE DERIVATIVES HAVING AN ANTICANCER ACTIVITY
  申请人：Agios Pharmaceuticals, Inc.

  公开号：EP3708169A1

  公开（公告）日：2020-09-16

  Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.

  本文描述了包含调节丙酮酸激酶 M2（PKM2）的化合物和组合物。本文还描述了使用调节 PKM2 的化合物治疗癌症的方法。
• Therapeutic compounds and compositions
  申请人：AGIOS PHARMACEUTICALS, INC

  公开号：US10029987B2

  公开（公告）日：2018-07-24

  Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.

  本文描述了包含调节丙酮酸激酶 M2（PKM2）的化合物和组合物。本文还描述了使用调节 PKM2 的化合物治疗癌症的方法。